| External factors: | Rosuvastatin |
| Aging type: | Prevent |
| Aging characteristic: |
| Category: | Chemical compounds |
| Phenotype: | Aging |
| Experiment: | SA-β-gal activity assay//Histological staining //Multiplex cytokine assay |
| Description: | Cotreatment of tissues with both simvastatin and rosuvastatin reduced the number of SA-β- Gal staining cells to that seen in controls, suggesting that a reduction in p38MAPK activation decreased senescence.Cotreatments of fetal membranes with rosuvastatin had more impact on fetal membrane SASP markers levels. There was a reduction in levels of GM- CSF and TNF- α. |
| Target gene: | P38MAPK |
| R-EF-Target gene: | Downregulation |
| Official symbol(s): | P38MAPK |
| Target gene experiment: | Western blot |
| Target gene description: | Cotreatment of CSE with simvastatin (CSE 155 ± 10.17, CSE + S100 = 108.9 ± 32.54, CSE + S200 = 76.79 ± 14.13, all P < .05) and rosuvastatin (CSE = 155 ± 10.17, CSE + R100 = 88.29 ± 9.177, CSE + R200 = 85.49 ± 5.77, all P < .05) significantly decreased p38MAPK activation compared to CSE . |
| Regulatory pathway: | -- |
| R-EF-Pathway: | -- |
| Pathway experiment: | -- |
| Pathway description: | -- |
Annotation: